|Posted by JJ The Psychotherapist on March 7, 2022 at 10:30 PM|
Pfizer Shot Protected Fewer Than 2 In 10 Kids, NY Health Dept Admits
According to a study conducted by the New York State Department of Health, Pfizer and BioNTech's COVID-19 vaccine protected only 12% of children aged five to eleven against COVID-19 infection.
The research looked at how the vaccination protected youngsters against the Omicron type of the virus during its peak from December 13th to January 24th. The 12 percent statistic, which corresponds to the vaccine protecting around one in ten children against the variation, comes as some states and schools implement immunization requirements for youngsters.
"During the Omicron variant's dominance, vaccine effectiveness against infection declined rapidly in New York State children aged 5 to 11 years, with low protection one month after full vaccination." "Among children aged 12 to 17, protection declined significantly, albeit more slowly than in younger children," according to the study, which is now awaiting peer review.
"From December 13th, 2021 to January 30th, 2022, vaccine effectiveness against cases declined from 66 percent to 51 percent for those 12 to 17 years and from 68 percent to 12 percent for those 5 to 11 years among 852,384 fully-vaccinated children 12 to 17 years and 365,502 children 5 to 11 years," the paper, which used data from hospitals across the state, continued.
Vaccine efficacy for 11-year-olds fell to 11% between January 24th and January 30th.
“Our data support vaccine protection against severe disease among children 5-11 years, but suggest rapid loss of protection against infection, in the Omicron variant era. Should such findings be replicated in other settings, review of the dosing schedule for children 5-11 years appears prudent.”
The increase in COVID-19 cases coincided with the state's implementation of rigorous mask rules for schools.
The lack of protection provided by the Pfizer vaccine is also the result of the corporation significantly extending its lobbying efforts to the federal government in terms of personnel and overall money invested.
Criticism of the company's COVID-19 vaccination has also been systematically blocked by social media "fact-checking" operations and mainstream media publications, both of which have demonstrated conflicts of interest with the pharmaceutical industry.